Jeff Yass’s Insight Molecular Diagnostics IMDX Stock Holding History

Jeff Yass’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-650	Closed	-$19K	–	13624
2022 Q1	$19K	Sell	650 -755	-54%	-$24.1K	﹤0.01%	12636
2021 Q4	$61K	Buy	1,405 +160	+13%	+$9.2K	﹤0.01%	12446
2021 Q3	$89K	Sell	1,245 -1,010	-45%	-$92.8K	﹤0.01%	12125
2021 Q2	$259K	Sell	2,255 -1,735	-43%	-$169K	﹤0.01%	11078
2021 Q1	$414K	Buy	3,990 +3,335	+509%	+$317K	﹤0.01%	9904
2020 Q4	$31K	Buy	+655	New	+$24K	﹤0.01%	10839

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's IMDX Position: Q2 2026 in Review

Jeff Yass sold out of Insight Molecular Diagnostics (IMDX) in Q2 2026, closing a stake of 56,093 shares — an estimated $184K sold.

Jeff Yass first reported a position in IMDX in Q1 2017 and held it in 19 quarters. The position peaked at $543K in Q4 2025. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Jeff Yass reported no remaining Insight Molecular Diagnostics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 56,093 Insight Molecular Diagnostics shares in Q2 2026, an estimated $184K.
Jeff Yass first reported a position in Insight Molecular Diagnostics in Q1 2017 and held it in 19 quarters.
Jeff Yass's Insight Molecular Diagnostics position peaked at $543K in Q4 2025.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.